Eli Lilly H-1B Visa Sponsorship 2026
Pharma & biotech · H-1B sponsor · FY2017–2026
🏢 Indianapolis, IN HQ🌐 lilly.com
Does Eli Lilly sponsor H-1B visas and green cards?
Yes. Eli Lilly has filed 1,620 H-1B LCAs and 136 PERM green-card cases with the U.S. Department of Labor between FY2017 and FY2026. In FY2025–2026 Eli Lilly filed 848 H-1B LCAs at a median base salary of $136,000, about 12% above the national H-1B median of $121,966 for the same period, and 50 green-card cases were decided.
H-1B pay & filings by year
Median base salary (line) and H-1B filing volume (bars), by fiscal year
Show the numbers behind this chart
| Fiscal year | H-1B LCA filings | Median base salary |
|---|---|---|
| FY2026 (partial) | 319 | $142k |
| FY2025 | 529 | $132k |
| FY2024 | 249 | $125k |
| FY2023 | 178 | $125k |
| FY2022 | 138 | $122k |
| FY2021 | 58 | $121k |
| FY2020 | 56 | $123k |
| FY2019 | 23 | $120k |
| FY2018 | 38 | $117k |
| FY2017 | 32 | $113k |
A fiscal year marked partial is still in progress, so its total is lower than a complete year and the two are not comparable.
H-1B wage floor & filing outcomes
What this employer pays against the DOL legal minimum, how senior the roles are, and how the filings were decided
Roles they file for
Where they hire
Green-card (PERM) pay & filings by year
Median green-card offer (line) and PERM filing volume (bars), by fiscal year †
Show the numbers behind this chart
| Fiscal year | PERM filings | Median base salary |
|---|---|---|
| FY2026 (partial) | 24 | $130k |
| FY2025 | 26 | $114k |
| FY2024 | 9 | $135k |
| FY2023 | 24 | $137k |
| FY2022 | 4 | $120k |
| FY2021 | 26 | $120k |
| FY2020 | 5 | $123k |
| FY2019 | 2 | $125k |
| FY2018 | 14 | $113k |
| FY2017 | 2 | $105k |
Green-card route and outcomes
Worker backgrounds · FY2017–2024
Where their green-card (PERM) workers studied & came from
Patents
- Granted
- 8
- US patents
- Published, not yet granted
- —
- applications
- Most recent grant
- April 7, 2026
- Top area
- Acyclic or carbocyclic compounds2
Pay against the local market
Eli Lilly’s 10 most-filed occupations and metros. Its median base salary is 136% of the local BLS median for the same work.
| Occupation | Metro | Filings | Eli Lilly pay | Local BLS median‡ | vs market |
|---|---|---|---|---|---|
| Statisticians | Indianapolis, IN | 204 | $143,534 | $102,083 | 141% |
| Software Developers | Indianapolis, IN | 112 | $119,083 | $105,811 | 113% |
| Chemists | Indianapolis, IN | 97 | $126,504 | $71,808 | 176% |
| Data Scientists | Indianapolis, IN | 78 | $126,538 | $89,210 | 142% |
| Industrial Engineers | Indianapolis, IN | 58 | $103,160 | $97,150 | 106% |
| Computer Occupations, All Other | Indianapolis, IN | 46 | $114,922 | $100,104 | 115% |
| Biological Scientists, All Other | Indianapolis, IN | 42 | $106,865 | $92,022 | 116% |
| Medical Scientists | Indianapolis, IN | 30 | $166,422 | $87,442 | 190% |
| Engineers, All Other | Indianapolis, IN | 29 | $110,800 | $109,866 | 101% |
| Biological Scientists, All Other | Boston, MA | 26 | $149,550 | $103,120 | 145% |
About Eli Lilly
Eli Lilly is a global pharmaceutical company known for diabetes and obesity treatments (Mounjaro, Zepbound) and a deep drug pipeline. Heavy pharma R&D makes it a long-running, high-volume H-1B sponsor.
- Legal name
- ELI LILLY & Co
- Listed
- NYSE: LLY
- Incorporated in
- Indiana
- Headquarters
- Lilly Corporate Ctr, Indianapolis, IN 46285
- Industry
- Pharma & biotech
- Employees (US, est)
- 21,803 (2024)
- Revenue FY2025
- $65.2B +45% from $45.0B
- Net income FY2025
- $20.6B +95% from $10.6B
- R&D FY2025
- $13.3B (20% of revenue)
China is the largest country of citizenship on its green-card filings, 39% of 136.
Eli Lilly pays a median H-1B base of $127,608 across FY2017–2026, about 19% above the typical Pharma & biotech sponsor.
H-1B sponsors similar to Eli Lilly
| Employer | Filings, all years | Recent filings | Median base | New employment | Level III-IV roles |
|---|---|---|---|---|---|
| Amgen | 3,981 | 745 | $138k | 247 | 46% |
| Memorial Sloan Kettering Cancer Center | 2,624 | 432 | $85k | 184 | 35% |
| UT Southwestern Medical Center | 2,486 | 661 | $72k | 308 | 6% |
| Eli Lilly | 1,620 | 848 | $136k | 353 | 73% |
| Bayer | 1,604 | 335 | $140k | 87 | 87% |
| Regeneron | 1,497 | 505 | $155k | 147 | 41% |
| AstraZeneca | 1,470 | 255 | $149k | 95 | 43% |
